All In Biotech

Free tool

FAERS Monitor: Ultomiris

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761108 or its brand name (Ultomiris, Ravulizumab-Cwvz). Reports on generic versions are filed under their own applications.

Reports

14,195

Serious

8,138

57% of reports

Hospitalization

2,863

Death reported

1,058

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue1,819
  • asthenia925
  • drug ineffective775
  • headache772
  • death677
  • off label use581
  • dyspnoea548
  • muscular weakness532
  • myasthenia gravis511
  • malaise483
  • pain452
  • haemoglobin decreased423
  • back pain395
  • feeling abnormal379
  • diarrhoea368

Reports by year received

View as table
YearReports
20111
20182
2019599
2020434
2021433
2022512
20232,079
20244,319
20253,090
20262,726

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,964 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myasthenia gravisSignal511100.091.646,843
muscular weaknessSignal5327.06.42,713
haemoglobin decreasedSignal4236.15.61,810
astheniaSignal9253.73.41,806
fatigueSignal1,8193.53.33,307
back painSignal3952.52.3365
feeling abnormalSignal3792.32.1294
headache7721.81.7296
malaise4831.61.5120
dyspnoea5481.41.374
death6771.21.116
pain4521.11.03
off label use5811.00.90
drug ineffective7750.90.816
diarrhoea3680.80.811

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.